Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$22.82 -1.2%	$20.56	$17.24 ▼ $28.56	$14.63B	0.96	1.17 million shs	1.11 million shs
HZNP Horizon Therapeutics Public	$116.30	$115.72	$60.03 ▼ $116.38	$26.63B	1.03	2.50 million shs	N/A
JAZZ Jazz Pharmaceuticals	$108.50 -1.6%	$107.84	$95.49 ▼ $148.06	$6.57B	0.33	834,460 shs	478,127 shs
ZTS Zoetis	$164.27 -2.7%	$158.67	$139.70 ▼ $200.33	$73.13B	0.94	2.55 million shs	2.97 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	0.00%	+2.79%	+16.13%	+11.26%	-14.76%
HZNP Horizon Therapeutics Public	0.00%	0.00%	0.00%	0.00%	0.00%
JAZZ Jazz Pharmaceuticals	0.00%	-2.37%	+2.29%	-21.35%	-2.27%
ZTS Zoetis	0.00%	-3.46%	+2.50%	+1.82%	-6.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	3.8235 of 5 stars	3.3	5.0	0.0	0.0	2.4	0.0	3.1
HZNP Horizon Therapeutics Public	1.138 of 5 stars	0.0	0.0	0.0	3.2	0.6	1.7	1.9
JAZZ Jazz Pharmaceuticals	4.9629 of 5 stars	4.5	2.0	0.0	4.0	3.3	3.3	3.1
ZTS Zoetis	4.6435 of 5 stars	3.6	3.0	4.2	0.4	3.7	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.69	Moderate Buy	$39.17	71.63% Upside
HZNP Horizon Therapeutics Public	0.00	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	2.92	Moderate Buy	$184.00	69.59% Upside
ZTS Zoetis	3.10	Buy	$212.75	29.51% Upside

Current Analyst Ratings Breakdown

Latest HZNP, JAZZ, ZTS, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
6/3/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
5/12/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$182.00 ➝ $172.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$167.00 ➝ $155.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$176.00 ➝ $147.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$183.00 ➝ $166.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$200.00 ➝ $200.00
5/7/2025	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$189.00 ➝ $170.00
4/14/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$180.00 ➝ $165.00
4/10/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$210.00 ➝ $210.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$3.12B	4.70	$1.54 per share	14.80	$8.04 per share	2.84
HZNP Horizon Therapeutics Public	$3.63B	7.34	$7.05 per share	16.49	$22.38 per share	5.20
JAZZ Jazz Pharmaceuticals	$4.06B	1.62	$22.10 per share	4.91	$59.36 per share	1.83
ZTS Zoetis	$9.29B	7.88	$7.38 per share	22.26	$10.65 per share	15.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.76	13.11	12.82	2.65	36.30%	16.78%	13.79%	8/14/2025 (Estimated)
HZNP Horizon Therapeutics Public	$521.48M	$1.87	62.19	20.55	3.96	12.02%	20.46%	11.52%	N/A
JAZZ Jazz Pharmaceuticals	$414.83M	$7.50	15.28	5.80	1.04	11.60%	29.30%	9.72%	7/30/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	30.03	24.34	2.78	26.86%	53.82%	18.86%	8/5/2025 (Estimated)

Latest HZNP, JAZZ, ZTS, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/6/2025	Q1 2025	JAZZ Jazz Pharmaceuticals	$4.65	$1.68	-$2.97	-$1.52	$984.16 million	$897.84 million
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
HZNP Horizon Therapeutics Public	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZTS Zoetis	$2.00	1.22%	N/A	35.91%	14 Years

Latest HZNP, JAZZ, ZTS, and GMAB Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	5.25	5.24
HZNP Horizon Therapeutics Public	0.48	4.27	4.09
JAZZ Jazz Pharmaceuticals	1.46	4.26	3.74
ZTS Zoetis	1.09	1.75	1.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
HZNP Horizon Therapeutics Public	80.37%
JAZZ Jazz Pharmaceuticals	89.14%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
HZNP Horizon Therapeutics Public	2.20%
JAZZ Jazz Pharmaceuticals	4.20%
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	1,660	641.22 million	651.58 million	Optionable
HZNP Horizon Therapeutics Public	2,115	228.99 million	223.96 million	Optionable
JAZZ Jazz Pharmaceuticals	3,200	60.51 million	57.92 million	Optionable
ZTS Zoetis	13,800	445.21 million	447.08 million	Optionable

HZNP, JAZZ, ZTS, and GMAB Headlines

Recent News About These Companies

Mn Services Vermogensbeheer B.V. Sells 12,400 Shares of Zoetis Inc. (NYSE:ZTS)

June 15 at 9:02 AM | marketbeat.com

Vaughan Nelson Investment Management L.P. Has $200.06 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 14 at 8:40 AM | marketbeat.com

Raub Brock Capital Management LP Sells 3,028 Shares of Zoetis Inc. (NYSE:ZTS)

June 14 at 8:40 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Bought by Campbell Newman Asset Management Inc.

June 14 at 7:33 AM | marketbeat.com

Tritonpoint Wealth LLC Sells 3,053 Shares of Zoetis Inc. (NYSE:ZTS)

June 14 at 7:24 AM | marketbeat.com

Stock Yards Bank & Trust Co. Boosts Position in Zoetis Inc. (NYSE:ZTS)

June 14 at 7:15 AM | marketbeat.com

Krilogy Financial LLC Takes $1.96 Million Position in Zoetis Inc. (NYSE:ZTS)

June 14 at 5:45 AM | marketbeat.com

1,777 Shares in Zoetis Inc. (NYSE:ZTS) Bought by Stanley Laman Group Ltd.

June 14 at 5:28 AM | marketbeat.com

SG Americas Securities LLC Has $3.42 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 14 at 4:05 AM | marketbeat.com

Osprey Private Wealth LLC Purchases 3,175 Shares of Zoetis Inc. (NYSE:ZTS)

June 13 at 7:24 AM | marketbeat.com

Willis Investment Counsel Acquires 15,240 Shares of Zoetis Inc. (NYSE:ZTS)

June 13 at 6:14 AM | marketbeat.com

Thomasville National Bank Has $13.88 Million Position in Zoetis Inc. (NYSE:ZTS)

June 13 at 6:03 AM | marketbeat.com

Ferguson Wellman Capital Management Inc. Sells 2,326 Shares of Zoetis Inc. (NYSE:ZTS)

June 13 at 5:37 AM | marketbeat.com

Fifth Third Bancorp Has $31.68 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 13 at 5:09 AM | marketbeat.com

Simon Quick Advisors LLC Buys 1,818 Shares of Zoetis Inc. (NYSE:ZTS)

June 13 at 5:09 AM | marketbeat.com

CX Institutional Lowers Holdings in Zoetis Inc. (NYSE:ZTS)

June 13 at 4:54 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Assenagon Asset Management S.A.

June 13 at 4:35 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Receives Average Rating of "Buy" from Analysts

June 13 at 2:24 AM | marketbeat.com

Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing

June 12 at 7:16 PM | zacks.com

Here's How Much a $1000 Investment in Zoetis Made 10 Years Ago Would Be Worth Today

June 12 at 10:24 AM | msn.com

Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term

June 11, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HZNP, JAZZ, ZTS, and GMAB Company Descriptions

Genmab A/S NASDAQ:GMAB

$22.82 -0.27 (-1.17%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$22.81 -0.01 (-0.04%)

As of 06/13/2025 06:58 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Horizon Therapeutics Public NASDAQ:HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals NASDAQ:JAZZ

$108.50 -1.79 (-1.62%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$104.58 -3.92 (-3.61%)

As of 06/13/2025 07:05 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Zoetis NYSE:ZTS

$164.27 -4.55 (-2.70%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$164.32 +0.05 (+0.03%)

As of 06/13/2025 06:52 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time